<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139470">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801982</url>
  </required_header>
  <id_info>
    <org_study_id>A1481283</org_study_id>
    <nct_id>NCT01801982</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Follow Up Study For Subjects Who Received Sildenafil for Persistent Pulmonary Hypertension of the Newborn (PPHN)</brief_title>
  <official_title>A Follow Up Investigation For Patients Completing Study A1481276 To Investigate Developmental Progress 12 And 24 Months Following Completion Of Sildenafil Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single center study will monitor the developmental progress of PPHN patients who
      received iv sildenafil in study A1481276.  Two visits will be conducted, at 12 and 24 months
      following the end of study drug infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will monitor developmental progress of PPHN patients for 2 years following study
      treatment, using Bayley III and Hammersmith tools. Data will be explored with descriptive
      statistics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Physical Examination (Bayley Neurological Assessments, Ophthalmology Exam, Hearing)</measure>
    <time_frame>at 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Developmental progress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination (Bayley Neurological Assessments, Ophthalmology Exam, Hearing)</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Developmental progress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical History, to include clinically relevant hospital admissions</measure>
    <time_frame>at 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hearing test to be conducted by HCP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical History, to include clinically relevant hospital admissions</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hearing test to be conducted by HCP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>safety</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Pulmonary Hypertension, Persistent, of the Newborn</condition>
  <arm_group>
    <arm_group_label>non-interventional</arm_group_label>
    <description>non-interventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional</description>
    <arm_group_label>non-interventional</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients who took part in study A1481276 following PPHN treatment with IV
        sildenafil
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subject who received sildenafil treatment in study A1481276.

          -  Signed and dated informed consent document by legal guardian.

        Exclusion Criteria:

          -  Any subject who did not receive sildenafil treatment during study A1481276.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Great Ormond Street Hospital, Paediatric Intensive Care</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481283&amp;StudyName=A%20Non-Interventional%20Follow%20Up%20Study%20For%20Subjects%20Who%20Received%20Sildenafil%20for%20Persistent%20Pulmonary%20Hypertension%20of%20the%20Newborn%20%28PPHN%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPHN; development progress after PPHN; developmental progress after sildenafil.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
